FDA reviews potential accelerated pathways for approval for Compass Pathways.
4 reports, 4 independent
Updated Thu 00:00
No new developments lately
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA reviews potential accelerated pathways for approval for Compass Pathways.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Compass Pathways NDA submitted to FDA; launch hinges on DEA rescheduling.1 source
FDA reviewed potential accelerated pathways for Compass Pathways on August 1, 2025.1 source
Keep exploring
The entities involved
- FDA
-
Compass Pathways
mental health care company
Nothing else this week.
Related events
- FDA approval enables commercial opportunity involving CBRE Group.
- Experimental therapies require approval from the FDA.
- Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
Coverage
Newest first; wire copies grouped- dailypolitical.com
- yahoo.com
- medicaldaily.com
- GuruFocus.comCompass Pathways PLC (CMPS) Q2 2025 Earnings Call Highlights: Clinical Success and Strategic ... Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full